Home Ingredients SAMe (S-Adenosyl-L-Methionine)
Joint HealthMood & Mental Health

SAMe (S-Adenosyl-L-Methionine)

Evidence Level
Moderate
4 Clinical Trials
6 Documented Benefits
3/5 Evidence Score

S-Adenosyl-L-Methionine (SAMe) is a naturally occurring compound in the body, synthesized from methionine and adenosine triphosphate (ATP). It plays a critical role in methylation processes, supporting neurotransmitter synthesis, liver detoxification, and joint health. As a dietary supplement, SAMe is used to support healthy mood, promote healthy liver function, and support joint comfort. It has also been studied in research settings for depression and osteoarthritis. Typical doses range from 400–1600 mg daily, but effects vary, and it may cause side effects like nausea or insomnia. SAMe may interact with antidepressants or other medications. Consult a healthcare provider before use, especially with medical conditions or concurrent medications.

Studied Dose 400–800 mg/day for depression; 600–1,200 mg/day for osteoarthritis; taken on empty stomach
Active Compound S-Adenosyl-L-Methionine

Benefits

Mood Support

SAMe helps support healthy mood by contributing to the production of neurotransmitters such as serotonin and dopamine. A systematic review and meta-analysis has examined SAMe in the research context of depression; this is provided as scientific background rather than a treatment claim.

Supported by Trial 1, Trial 2

Joint Health and Comfort

SAMe is involved in cartilage-supporting metabolic pathways and may help support joint comfort and mobility. Human research in osteoarthritis exists but is not represented among the references cited on this page, so this use should be read as a research context rather than an established benefit here.

Supported by Trial 3, Trial 2

Liver Function

SAMe participates in methylation and glutathione production, processes that support healthy liver function. Any use in clinical liver conditions such as cholestasis, fatty liver, or hepatitis is a medical/research context and is not represented among the references cited on this page.

Supported by Trial 3, Trial 1

Cognitive Health

SAMe supports methylation processes relevant to neurotransmitter production and healthy cognitive function. Evidence for any role in cognitive decline is preliminary and is not represented among the references cited on this page.

Supported by Trial 2, Trial 3

Muscle Comfort

SAMe has been explored in research for muscle comfort and physical well-being. Evidence in fibromyalgia is preliminary and is not represented among the references cited on this page.

Supported by Trial 1, Trial 2

Methylation Support

SAMe is a key methyl donor in the body, supporting DNA repair, gene expression, and detoxification processes, which are critical for overall health.

Supported by Trial 2, Trial 4

Mechanism of action

1

Methylation Reactions

SAMe is a universal methyl donor, transferring methyl groups to molecules like DNA, proteins, phospholipids, and neurotransmitters. Modifies DNA and histones to control gene activity. Supports production of serotonin, dopamine, and norepinephrine, impacting mood and cognitive function. Methylates phospholipids, maintaining cell membrane integrity. Facilitates the metabolism of toxins and drugs in the liver.

2

Transsulfuration Pathway

SAMe is converted into homocysteine, which enters the transsulfuration pathway to produce glutathione, a potent antioxidant. Enhances detoxification and reduces oxidative stress in conditions like fatty liver disease or hepatitis. Protects cells from oxidative damage.

3

Polyamine Synthesis

SAMe contributes to the synthesis of polyamines. Supports tissue regeneration, including cartilage in osteoarthritis. May aid in maintaining neuronal health.

4

Anti-inflammatory Effects

SAMe reduces pro-inflammatory cytokines (e.g., TNF-α) and increases anti-inflammatory mediators. This may help support comfortable joint function and overall physical well-being.

5

Neurotransmitter Modulation

By supporting methylation, SAMe enhances the synthesis and metabolism of neurotransmitters, which may help support healthy mood and cognitive function.

Clinical trials

1
SAMe as SSRI Augmentation for Depression — Clinical Trial
PubMed

Randomized, double-blind, placebo-controlled trial (NCT00093847) evaluating SAMe as adjunct to serotonin reuptake inhibitors in depressed patients. (Am J Psychiatry)

Depressed adults on SSRIs.

SAMe augmentation modestly improved response and remission rates vs placebo when added to SSRIs. Note: depression management primarily uses SSRIs/SNRIs/atypical antidepressants + CBT/psychotherapy. SAMe is a reasonable adjunctive option for partial responders.

2
SAMe Added to Antidepressants for Depression: Randomized Trial
PubMed

Six-week double-blind, placebo-controlled add-on trial (NCT01912196, the Horizon Study) of SAMe 800 mg/day added to ongoing antidepressant medication versus placebo in 234 adults with major depressive disorder who had responded inadequately to their antidepressant. Funded by the manufacturer, MSI Methylation Sciences.

234 adults with MDD taking antidepressants.

There was no statistically significant difference between SAMe and placebo on any of the three depression rating scales in the main (intention-to-treat) analysis. A benefit appeared only in a post-hoc subgroup of participants enrolled during the first half of the study. SAMe was well tolerated, with mostly mild gastrointestinal effects.

3
SAMe vs Celecoxib for Knee OA — Clinical Trial
PubMed

Randomized double-blind crossover trial (Najm 2004, BMC Musculoskeletal Disorders) comparing SAMe 1,200 mg/day with celecoxib 200 mg/day over 16 weeks in 61 patients with knee osteoarthritis. There was no placebo arm.

61 knee osteoarthritis patients.

Celecoxib reduced pain faster in the first month, but by the second month SAMe and celecoxib gave comparable pain and function improvement. SAMe had the slower onset. The trial had no placebo group, so it shows similarity to an active drug rather than a placebo-controlled effect.

4
SAMe for Depression in Parkinson's Disease — Open-Label Pilot
PubMed

Open-label pilot study (Di Rocco et al. 2000, Movement Disorders) of SAMe 800 to 3,600 mg/day for 10 weeks in 13 patients with Parkinson's disease and depression (11 completed). No placebo control and not blinded.

13 Parkinson's disease patients with depression (11 completed).

Modest improvements in depression scores. Critical caveat: open-label (no placebo, not blinded) — inflated effect estimate. Pilot only. Note: PD-related depression is challenging; SSRIs first-line; consider drug-drug interactions in PD pharmacotherapy.

Side effects and drug interactions

Common Potential side effects

Gastrointestinal: Nausea, diarrhea, upset stomach, bloating, or mild abdominal pain are frequently reported, especially at higher doses.
Nervous System: Headache, dizziness, or mild insomnia may occur, particularly if taken later in the day due to its potential to increase energy or alertness.
Psychiatric: Anxiety, restlessness, or irritability can occur, especially in sensitive individuals or at high doses.

Important Drug interactions

Antidepressants (MAOIs, SSRIs, SNRIs, tricyclics) — serious serotonin syndrome risk; never combine with MAOIs; use extreme caution with SSRIs
Levodopa — SAMe may reduce levodopa efficacy in Parkinson's disease; avoid concurrent use
Warfarin — SAMe may enhance anticoagulant effects; monitor INR closely

Featured in these supplement guides

Joint Pain→

More Joint Health Ingredients

Joint Health
Boswellia Serrata
Boswellia Serrata is a resin extract from the boswellia tree (Indian frankincense) used in…
Joint Health
Casperome® (Boswellia Phytosome — Indena)
Casperome® is Indena's phytosome-formulated Boswellia serrata extract — addressing the maj…
Joint Health
Boswellin® / Boswellin® Super (Standardized Boswellia serrata — Sabinsa)
Boswellin® is Sabinsa's branded Boswellia serrata gum resin extract, available in multiple…
Joint Health
Glucosamine
Glucosamine, a natural compound found in cartilage, is commonly supplemented as glucosamin…

Explore Other Ingredients

Muscle & Recovery
L-Glutamine
L-glutamine is the most abundant amino acid in the body and the primary metabolic fuel for…
Antioxidant
Dandelion Root
Dandelion root is a traditional herb used to support liver and digestive health and as a g…
Antioxidant
Setria® Glutathione
Setria® is Kyowa Hakko's patented reduced L-glutathione (GSH) produced via fermentation —…

Related articles from our blog

📝 Article
How Long Until Supplements Actually Work?
The most common reason supplements "do not work" is that people quit before they ever had a chance to. Someone takes ash…
📝 Article
Supplement and Medication Interactions to Know
"It's natural, so it's safe with my medication." It is one of the most common, and most dangerous, assumptions in the su…
📝 Article
TMG (Betaine): Methylation, Homocysteine, and What It Really Does
TMG has quietly become a fixture in longevity and methylation stacks, usually sold as the thing you add to NMN to "keep…

Frequently asked questions about SAMe (S-Adenosyl-L-Methionine)

What is SAMe used for?

SAMe (S-adenosyl-L-methionine) is a compound the body makes from methionine, used for mood support, joint comfort, and liver health. It is involved in many methylation reactions throughout the body.

Does SAMe help with mood and joints?

SAMe has notable research supporting healthy mood and joint comfort, making it one of the better-studied compounds for these uses. It is typically taken for a few weeks before results are assessed.

How much SAMe should I take?

Mood studies use about 400 to 1,600 mg per day, and joint studies similar; it is taken on an empty stomach, and enteric-coated forms are preferred for stability. Start low and follow product labeling.

Is SAMe safe?

It is generally well tolerated; it can cause nausea or, in susceptible people, anxiety or (rarely) mania. It should not be combined with antidepressants or other serotonergic drugs without medical guidance, and those with bipolar disorder should avoid it. Check with your doctor.

What is SAMe?

S-Adenosyl-L-Methionine (SAMe) is a naturally occurring compound in the body, synthesized from methionine and adenosine triphosphate (ATP). It plays a critical role in methylation processes, supporting neurotransmitter synthesis, liver detoxification, and joint health.

What is the recommended dosage of SAMe?

The clinically studied dose is 400–800 mg/day for depression; 600–1,200 mg/day for osteoarthritis; taken on empty stomach Always follow the product label and check with a healthcare provider for personal advice.

Is SAMe safe, and does it have side effects?

For most healthy adults, SAMe is well tolerated at studied doses. Reported effects can include: Gastrointestinal: Nausea, diarrhea, upset stomach, bloating, or mild abdominal pain are frequently reported, especially at higher doses. Nervous System: Headache, dizziness, or mild insomnia may occur, particularly if taken later in the day due to its potential to increase energy… It may also interact with some medications. SAMe is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does SAMe interact with any medications?

Possible interactions include: Antidepressants (MAOIs, SSRIs, SNRIs, tricyclics) — serious serotonin syndrome risk; never combine with MAOIs; use extreme caution with SSRIs Levodopa — SAMe may reduce levodopa efficacy in Parkinson's disease; avoid concurrent use If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for SAMe?

NutraSmarts rates the evidence for SAMe as Moderate (3 out of 5). It is backed by 4 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Limveeraprajak N, Nakhawatchana S, Visukamol A, et al. Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2024;132:110985..PubMedUsed to support: Systematic review and meta-analysis of 23 randomized trials (2,183 participants): SAMe monotherapy reduced depressive symptoms more than placebo (SMD -0.58, moderate-certainty evidence), while SAMe added to antidepressants did not differ significantly from placebo, and SAMe did not differ significantly from standard antidepressants.
  2. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskelet Disord. 2004;5:6. doi: 10.1186/1471-2474-5-6.PubMedUsed to support: Randomized double-blind crossover trial in 61 patients with knee osteoarthritis: SAMe 1,200 mg/day matched celecoxib 200 mg/day for pain and function by the second month, with a slower onset and no placebo comparison.
  3. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942-948. doi: 10.1176/appi.ajp.2009.09081198.PubMedUsed to support: Six-week randomized, double-blind trial in 73 adults with major depressive disorder who had not responded to a serotonin reuptake inhibitor: adding SAMe 800 mg twice daily raised response and remission rates compared with adding placebo.
  4. Targum SD, Cameron BR, Ferreira L, MacDonald ID. An augmentation study of MSI-195 (S-adenosylmethionine) in Major Depressive Disorder. J Psychiatr Res. 2018;107:86-96. doi: 10.1016/j.jpsychires.2018.10.010.PubMedUsed to support: Manufacturer-funded six-week trial in 234 adults with major depressive disorder inadequately responding to antidepressants: SAMe 800 mg/day added to ongoing medication showed no significant benefit over placebo on any of three depression scales in the main analysis, with a positive result only in a post-hoc first-half subgroup.